Endo International received a notice from Nasdaq to delist its common stock in connection with its Chapter 11 restructuring under the U.S. Bankruptcy Code. Company's securities are now traded only on over-the-counter market under ticker ENDPQ. Earlier Endo International reported that shareholders should not expect any significant payouts after completion of...

Endo International filed for restructuring under Chapter 11 of the U.S. Bankruptcy Code. Company was able to reach an agreement with its first-priority secured creditors. However, it is unlikely that Endo International shareholders will receive any significant distributions once the Chapter 11 proceedings are completed and the shares are canceled.

Endo International reported a GAAP loss of $71.974 million in the first three months of 2022, compared to a profit of $41.524 million in the previous year. Revenue decreased by 9.1% to $652.259 million from $717.919 million a year earlier.

Endo International has acquired six injectable drug candidates in development from Nevakar Injectables. The deal amounted to $35 million. The drugs are in various stages of development, the first of which will be released in 2025.